治疗成人产后抑郁症新药brexanolone

Brexanolone:a new drug for adult women with postpartum depression

brexanolone是由Sage Therapeutics公司研发的一种γ-氨基丁酸A受体变构调节剂,其结构与内源性神经活性甾体别孕烯醇酮相同。2019年3月19日,FDA批准brexanolone用于产后抑郁症的成年女性。临床结果显示brexanolone对中重度产后抑郁症患者抑郁症状的缓解明显高于安慰剂组,重度产后抑郁症患者组在30 d时的抑郁症状缓解明显高于安慰剂组,而中度产后抑郁症患者组则无显著性差异。brexanolone可引起过度镇静和意识丧失,因此在输注期间应严密监测。本文对其药理作用、药动学、临床研究及安全性进行概述。

Brexanolone,developed by Sage Therapeutics,is a GABAA receptor modulator that was structurally identical to the endogenous neuroactive steroid allopregnanolone.Brexanolone received its first global approval by FDA for the treatment of postpartum depression in adult women on March 19,2019.It reduced depression symptoms more significantly in women with moderate to severe postpartum depression than in placebo group,and reduced depression symptoms at 30 days more significantly in women with severe postpartum depression than in placebo group.However,there was no statistically difference in patients with moderate postpartum depression.Brexanolone caused excessive sedation and loss of consciousness,therefore must be monitored throughout the infusion.This review summarizes the pharmacological effect,pharmacokinetics,clinical trials and safety of brexanolone.